Search Within
B7431
Applied Filters:
Keyword:'B7431'
Showing 1-30 of 40 results for "B7431" within Papers
Paul A Wender et al.
Organic letters, 16(19), 5140-5143 (2014-09-23)
Bryostatin 1, in clinical trials or preclinical development for cancer, Alzheimer's disease, and a first-of-its-kind strategy for HIV/AIDS eradication, is neither readily available nor optimally suited for clinical use. In preceding work, we disclosed a new class of simplified bryostatin
Total synthesis of bryostatin 1: a short route.
Soraya Manaviazar et al.
Angewandte Chemie (International ed. in English), 50(38), 8786-8789 (2011-07-14)
Jeremy Kortmansky et al.
Cancer investigation, 21(6), 924-936 (2004-01-23)
Modulation of PKC represents a novel approach to cancer therapy. Bryostatin-1 is a macrocyclic lactone derived from a marine invertebrate that binds to the regulatory domain of protein kinase C. Short-term exposure to bryostatin-1 promotes activation of PKC, whereas prolonged
Dan Zhao et al.
Cellular immunology, 271(2), 392-400 (2011-09-10)
The majority of melanoma cells express detectable levels of HLA class II proteins, and an increased threshold of cell surface class II is crucial for the stimulation of CD4+ T cells. Bryostatin-1, a protein kinase C (PKC) activator, has been
Noemi Kedei et al.
Biochemical pharmacology, 81(11), 1296-1308 (2011-04-05)
Bryostatin 1 has attracted considerable attention both as a cancer chemotherapeutic agent and for its unique activity. Although it functions, like phorbol esters, as a potent protein kinase C (PKC) activator, it paradoxically antagonizes many phorbol ester responses in cells.
N Kedei et al.
Biochemical pharmacology, 85(3), 313-324 (2012-11-14)
Bryostatin 1, like the phorbol esters, binds to and activates protein kinase C (PKC) but paradoxically antagonizes many but not all phorbol ester responses. Previously, we have compared patterns of biological response to bryostatin 1, phorbol ester, and the bryostatin
Karin von Schwarzenberg et al.
Cancer letters, 332(2), 295-303 (2010-08-03)
Natural compounds derived from marine organisms have shown a wide variety of anti-tumor effects and a lot of attention has been drawn to further development of the isolated compounds. A vast quantity of individual chemical structures from different organisms has
Weili Yan et al.
Cytokine, 52(3), 238-244 (2010-09-28)
Bryostatin-1 (Bryo-1), a PKC modulator, was previously shown to activate monocytes and lymphocytes to produce cytokines. In this report, we investigated the adjuvanticity of Bryo-1 both in vitro and in vivo. First, Bryo-1 was found to induce the release of
Abhik Sen et al.
The Journal of biological chemistry, 287(19), 15947-15958 (2012-03-20)
Synaptic loss is the earliest pathological change in Alzheimer disease (AD) and is the pathological change most directly correlated with the degree of dementia. ApoE4 is the major genetic risk factor for the age-dependent form of AD, which accounts for
Robert J Morgan et al.
Investigational new drugs, 30(2), 723-728 (2010-10-12)
The California Cancer Consortium has performed a Phase II trial of infusional bryostatin, a protein kinase C inhibitor isolated from the marine invertebrate bryozoan, Bugula Neritina, a member of the phylum Ectoprocta, in combination with cisplatin, in patients (pts) with
Tonia J Buchholz et al.
Chemistry & biology, 17(10), 1092-1100 (2010-11-03)
In vitro analysis of natural product biosynthetic gene products isolated from unculturable symbiotic bacteria is necessary to probe the functionalities of these enzymes. Herein, we report the biochemical characterization of BryR, the 3-hydroxy-3-methylglutaryl (HMG)-CoA synthase (HMGS) homolog implicated in β-branching at
Miao-Kun Sun et al.
The Journal of pharmacology and experimental therapeutics, 349(3), 393-401 (2014-03-25)
Fragile X syndrome (FXS) is caused by transcriptional silencing in neurons of the FMR1 gene product, fragile X mental retardation protein (FMRP), a repressor of dendritic mRNA translation. The lack of FMRP leads to dysregulation of synaptically driven protein synthesis
Gary E Keck et al.
Bioorganic & medicinal chemistry letters, 22(12), 4084-4088 (2012-05-15)
The role of the C(8) gem-dimethyl group in the A-ring of bryostatin 1 has been examined through chemical synthesis and biological evaluation of a new analogue. Assays for biological function using U937, K562, and MV4-11 cells as well as the
Yasuyuki Ogawa et al.
The Journal of organic chemistry, 78(1), 104-115 (2012-11-06)
The Prins cyclization of syn-β-hydroxy allylsilanes and aldehydes gives cis-2,6-disubstituted 4-alkylidenetetrahydropyrans as sole products in excellent yields regardless of the aldehyde (R″) or syn-β-hydroxy allylsilane substituent (R') used. By reversing the R″ and R' groups, complementary exocyclic stereocontrol can be
Signaling pathways involved in cognitive enhancement
Cognition, 11-42 (2015)
H Kim et al.
Neuroscience, 226, 348-355 (2012-09-19)
Activation of protein kinase C (PKC) by bryostatin-1 affects various functions of the central nervous system. We explored whether bryostatin-1 influenced synaptic plasticity via a process involving PKC. Our purpose was to examine whether bryostatin-1 affected the induction of hippocampal
Virpi Talman et al.
PloS one, 6(5), e20053-e20053 (2011-06-02)
Diacylglycerol (DAG)-mediated signaling pathways, such as those mediated by protein kinase C (PKC), are central in regulating cell proliferation and apoptosis. DAG-responsive C1 domains are therefore considered attractive drug targets. Our group has designed a novel class of compounds targeted
Paul A Wender et al.
Organic letters, 16(19), 5136-5139 (2014-09-23)
Bryostatin 1 is in clinical trials for the treatment of cancer and Alzheimer's disease and is a candidate for a first-in-class approach to HIV/AIDS eradication. It is neither readily available nor optimally suited for clinical use. Using a function oriented
Miao-Kun Sun et al.
CNS drug reviews, 12(1), 1-8 (2006-07-13)
Bryostatin-1 is a powerful protein kinase C (PKC) agonist, activating PKC isozymes at nanomolar concentrations. Pharmacological studies of bryostatin-1 have mainly been focused on its action in preventing tumor growth. Emerging evidence suggests, however, that bryostatin-1 exhibits additional important pharmacological
Bryostatin 1: differentiating agent from the depths.
R M Stone
Leukemia research, 21(5), 399-401 (1997-05-01)
Maria Eugenia Ariza et al.
The Journal of biological chemistry, 286(1), 24-34 (2010-11-03)
Bryostatin-1 (Bryo-1), a natural macrocyclic lactone, is clinically used as an anti-cancer agent. In this study, we demonstrate for the first time that Bryo-1 acts as a Toll-like receptor 4 (TLR4) ligand. Interestingly, activation of bone marrow-derived dendritic cells (in
S Grant
Frontiers in bioscience : a journal and virtual library, 2, d242-d252 (1997-06-01)
Modulation of ara-C-induced apoptosis in human leukemia cells by the macrocyclic lactone PKC activator bryostatin 1 occurs at multiple levels, and involves a variety of oncogenes and signalling pathways. Under some circumstances, bryostatin 1 may lead to enhanced conversion of
Azim Hossain et al.
Clinical & developmental immunology, 2011, 780839-780839 (2011-12-14)
While the defects in HLA class I-mediated Ag presentation by Burkitt lymphoma (BL) have been well documented, CD4+ T-cells are also poorly stimulated by HLA class II Ag presentation, and the reasons underlying this defect(s) have not yet been fully
Jarin Hongpaisan et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 31(2), 630-643 (2011-01-14)
Among the pathologic hallmarks of Alzheimer's disease (AD) neurodegeneration, only synaptic loss in the brains of AD patients closely correlates with the degree of dementia in vivo. Here, we describe a molecular basis for this AD loss of synapses: pathological
C Korin Bullen et al.
Nature medicine, 20(4), 425-429 (2014-03-25)
HIV-1 persists in a latent reservoir despite antiretroviral therapy (ART). This reservoir is the major barrier to HIV-1 eradication. Current approaches to purging the latent reservoir involve pharmacologic induction of HIV-1 transcription and subsequent killing of infected cells by cytolytic
Bryostatin-1 ameliorated experimental colitis in Il-10-/- Mice by protecting the intestinal barrier and limiting immune dysfunction
Zuo L, et al.
Journal of Cellular and Molecular Medicine, 23(8), 5588-5599 (2019)
P Yi et al.
Journal of molecular neuroscience : MN, 48(1), 234-244 (2012-06-16)
Activation of the α-secretase processing pathway of amyloid precursor protein (APP) is recognized as an important mechanism which diverts APP processing from production of beta-amyloid (Aβ) to non toxic sAPPα, decreasing Alzheimer's disease (AD) plaque formation and AD-associated cognitive deficits.
Moisés Pérez et al.
Current HIV research, 8(6), 418-429 (2010-07-20)
The persistence of latent HIV-infected cellular reservoirs represents the major hurdle to virus eradication on patients treated with HAART. It has been suggested that successful depletion of such latent reservoirs will require a combination of therapeutic agents that can specifically
B Douglas Smith et al.
Leukemia research, 35(1), 87-94 (2010-07-06)
Pharmacologic differentiating agents have had relatively limited clinical success outside of the use of ATRA in acute promyelocytic leukemia and DNA methyltransferase inhibitors in myelodysplastic syndromes. The differentiating effects of such agents can be enhanced in combination with lineage-specific growth
Jinfeng Cai et al.
eLife, 10 (2021-04-10)
The major barrier to curing HIV-1 infection is a small pool of latently infected cells that harbor replication-competent viruses, which are widely considered the origin of viral rebound when antiretroviral therapy (ART) is interrupted. The difficulty in distinguishing latently infected cells
Page 1 of 2